CO2022003556A2 - Análogos de compstatina y sus usos médicos - Google Patents
Análogos de compstatina y sus usos médicosInfo
- Publication number
- CO2022003556A2 CO2022003556A2 CONC2022/0003556A CO2022003556A CO2022003556A2 CO 2022003556 A2 CO2022003556 A2 CO 2022003556A2 CO 2022003556 A CO2022003556 A CO 2022003556A CO 2022003556 A2 CO2022003556 A2 CO 2022003556A2
- Authority
- CO
- Colombia
- Prior art keywords
- compstatin
- introduction
- analogs
- modifications
- inhibition activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19193925 | 2019-08-27 | ||
| EP20172189 | 2020-04-29 | ||
| PCT/EP2020/073905 WO2021037942A1 (en) | 2019-08-27 | 2020-08-26 | Compstatin analogues and their medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022003556A2 true CO2022003556A2 (es) | 2022-05-20 |
Family
ID=72178552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0003556A CO2022003556A2 (es) | 2019-08-27 | 2022-03-25 | Análogos de compstatina y sus usos médicos |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017385A2 (pt) * | 2018-02-27 | 2020-12-15 | Zp Spv 3 K/S | Análogos de compstatina, métodos e seus usos médicos |
| JP2023538807A (ja) * | 2020-07-16 | 2023-09-12 | セッドぺー エスぺーヴェー 3 カー/エス | 補体因子c3の阻害剤及びそれらの医学的使用 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023048151A1 (ja) * | 2021-09-22 | 2023-03-30 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する環状ペプチド |
| EP4622992A1 (en) * | 2022-11-24 | 2025-10-01 | Amyndas Pharmaceuticals US LLC | Compstatin analogs for vector-based therapy |
| WO2026112532A1 (en) * | 2024-11-22 | 2026-05-28 | Apellis Pharmaceuticals, Inc. | Compstatin analogs |
| US20260234189A1 (en) | 2025-01-24 | 2026-08-13 | Boehringer Ingelheim International Gmbh | Novel and stable compstatin analogues |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999013899A1 (en) * | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| US7989589B2 (en) | 2002-09-20 | 2011-08-02 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
| CN101325963B (zh) | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
| ES2390828T3 (es) | 2005-11-28 | 2012-11-16 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| WO2008153963A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-c3 complex and use for rational drug design |
| WO2010039690A1 (en) * | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| CA2813049A1 (en) * | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| PL2753636T3 (pl) | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| WO2014100407A1 (en) * | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Compstatin analogs |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US20180057538A1 (en) * | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Potent and highly soluble pegylated compstatin peptides |
| BR112020017385A2 (pt) * | 2018-02-27 | 2020-12-15 | Zp Spv 3 K/S | Análogos de compstatina, métodos e seus usos médicos |
-
2020
- 2020-08-26 ES ES23192007T patent/ES3049784T3/es active Active
- 2020-08-26 MX MX2022002433A patent/MX2022002433A/es unknown
- 2020-08-26 AU AU2020338688A patent/AU2020338688B2/en active Active
- 2020-08-26 KR KR1020227010019A patent/KR20220066287A/ko active Pending
- 2020-08-26 EP EP23192007.5A patent/EP4272751B1/en active Active
- 2020-08-26 BR BR112022003760A patent/BR112022003760A2/pt unknown
- 2020-08-26 CN CN202080067713.3A patent/CN114630836A/zh active Pending
- 2020-08-26 CA CA3148536A patent/CA3148536A1/en active Pending
- 2020-08-26 US US17/637,392 patent/US20220306695A1/en active Pending
- 2020-08-26 WO PCT/EP2020/073905 patent/WO2021037942A1/en not_active Ceased
- 2020-08-26 EP EP20760472.9A patent/EP4021921A1/en active Pending
- 2020-08-26 JP JP2022513150A patent/JP7711044B2/ja active Active
- 2020-08-27 TW TW109129392A patent/TW202128731A/zh unknown
-
2022
- 2022-02-23 IL IL290858A patent/IL290858A/en unknown
- 2022-03-25 CO CONC2022/0003556A patent/CO2022003556A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290858A (en) | 2022-04-01 |
| EP4272751B1 (en) | 2025-09-24 |
| US20220306695A1 (en) | 2022-09-29 |
| KR20220066287A (ko) | 2022-05-24 |
| JP2022545916A (ja) | 2022-11-01 |
| JP7711044B2 (ja) | 2025-07-22 |
| EP4021921A1 (en) | 2022-07-06 |
| ES3049784T3 (en) | 2025-12-18 |
| EP4272751C0 (en) | 2025-09-24 |
| TW202128731A (zh) | 2021-08-01 |
| WO2021037942A1 (en) | 2021-03-04 |
| EP4272751A2 (en) | 2023-11-08 |
| MX2022002433A (es) | 2022-05-19 |
| AU2020338688A1 (en) | 2022-03-24 |
| CA3148536A1 (en) | 2021-03-04 |
| EP4272751A3 (en) | 2024-02-14 |
| AU2020338688B2 (en) | 2026-06-04 |
| BR112022003760A2 (pt) | 2022-05-31 |
| CN114630836A (zh) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020011027A2 (es) | Análogos de compstatina y sus usos médicos | |
| BR112022003760A2 (pt) | Análogos de compstatina e seus usos médicos | |
| DOP2021000197A (es) | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea | |
| CO2023001411A2 (es) | Inhibidores del factor c3 del complemento y sus usos médicos | |
| CY1125528T1 (el) | Νεα glp-1 αναλογα | |
| BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
| AR069409A1 (es) | Variantes de peptidos natriureticos de tipo c | |
| PE20140159A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| MX9205985A (es) | Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen. | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| MX370645B (es) | Agonistas npr-b novedosos. | |
| AR081339A1 (es) | Conjugados peptidicos | |
| PE20160683A1 (es) | Analogos de glucagon acilados | |
| PE20200678A1 (es) | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) | |
| AR076973A1 (es) | Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c) | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| AR063263A1 (es) | Agentes tensioactivos reconstituidos | |
| CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
| PE20210185A1 (es) | Apirasas solubilizadas, metodos y usos | |
| BR112022012057A2 (pt) | Novos métodos de entrega celular | |
| MX2015002994A (es) | Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| DOP2017000287A (es) | Analogos glp-1 lipidados resistentes a proteasa |